Compare Revvity Inc (RVTY) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs T Rowe Price Group Inc — how do they compare? Revvity Inc trades at $116.29 (market cap $12.91B), while T Rowe Price Group Inc trades at $111.11 (market cap $24.26B). The key difference: T Rowe Price Group Inc is the larger of the two by market cap, and T Rowe Price Group Inc pays the higher dividend (4.57%). Which is the better fit depends on your goals.
| RVTY | TROW | |
|---|---|---|
Market Cap | $12.91B | $24.26B |
Sector | Technology | Financials |
52-Week High | $117.75 | $121.68 |
52-Week Low | $82.26 | $86.19 |
Enterprise Value | $15.23B | $21.46B |
Dividend Yield | 0.24% | 4.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.
The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.
T. Rowe Price (TROW) trades at $111.17, down 2.29% on the day, with a bearish technical signal driven by moving averages. Recent Q2 2026 earnings beat expectations with EPS of $2.57, supported by record assets under management. Revenue and net income have shown steady growth, with 2025 revenue at $7.31B and net income at $2.09B. The company maintains strong profitability, with a net margin of 29.26% and ROE of 20.1%. Valuation ratios appear reasonable, with a P/E of 11.42 and EV/EBITDA of 6.75. Dividends remain consistent, with a recent quarterly payment of $1.30 declared.
The outlook for TROW is mixed; fundamental strength from earnings growth and solid cash flow supports potential upside, but technical bearishness and analyst caution pose near-term risks. Investment opportunity lies in its undervalued metrics and dividend reliability, while risks include expense pressures and market volatility affecting asset flows. The consensus price target of $112.17 suggests limited upside from current levels, emphasizing a hold stance amid balanced factors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
